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Old Drug, new strength
Tenectaplase (Metalyse)
Also available now as 8000 unit vial.
New drugs







Myoclonic seizure; adjunct: initial 500mg orally twice daily; increase daily doses by
1000mg every 2 weeks to reach target dose of 3000mg/day
Partial seizure; adjunct 500mg twice daily orally; may increase dosage by 1000mg/day
every 2 weeks to a max recommended daily dose of 3000mg/day
Dosage, Paediatric usual
Tablets safety and efficacy not established in children less than 4 years.
Myoclonic seizure; Adjunct: 12y and older; initial 500mg twice daily; increase dosage by
1000mg every 2 weeks to reach target dose of 3000mg/day
Partial seizure; Adjunct: (4-15 years) 10mg/kg twice daily; may increase dosage by
20mg/kg/day in 2 divided doses every 2 weeks to a max of 60mg/kg/day ( in 2 divided
doses)
Partial seizure; Adjunct: (16 years and older) 500mg twice daily; may increase dosage by
1000mg/day every 2 weeks to a maximum daily dosage of 3000mg/day
Dosage Adjustments
Dosage adjustments required enquire with Pharmacy Medicine Information Centre
Administration




Hypersensitivity to levetiracetam or any component of the product
Precautions
Concomitant use of oral contraceptives, congestive heart failure or cardiac







Adverse reactions to drugs are common among patients with HIV- related tuberculosis especially if taking
HAART concomitantly.
Rash, fever and hepatitis are common side effects of antituberculosis drugs especially rifampicin,
isoniazid and pyrazinamide. The NNRTI and co-trimoxazole may also cause similar features
 
Hepatoxicity
Hepatoxicity is a common and potentially serious adverse event. It is defined as:
1. A serum AST or ALT level of more than three times upper limit of normal in the presence
of symptoms, or
2. A serum AST or ALT greater than five times the upper limit of normal in the absence of
symptoms.
If hepatitis develops then all potentially hepatoxic drugs including isoniazid, rifampicin, pyrazinamide
and other antivirals and co-trimaxazole, should be stopped immediately.
As resolution of the hepatitis may be prolonged and until the cause of the hepatitis is identified then, if
necessary, it would be reasonable to treat with two or more antituberculosis medications without
significant risk of hepatoxicity, such as ethambutol, streptomycin, amikacin/kanamycin, capreomycin,
or a fluoroquinolone.
Monitoring of serum AST (or ALT) and bilirubin and any symptoms should be performed frequently
and once the AST level drops to less than two times the upper limit of normal and symptoms have
significantly improved, then first line medications can be started using a reintroduction regimen.
If the drugs cannot be started or the initial reaction was life threatening then an alternative regimen
can be used.
Guidelines for the reintroduction of anti-tuberculous chemotherapy following elevation of liver function tests
or cutaneous reaction grade 1-3
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